CAMBRIDGE, Mass.--(BUSINESS WIRE)--Euthymics Bioscience, Inc. today announced completion of enrollment in the advanced clinical study of its lead product candidate amitifadine (formerly called EB-1010), a novel serotonin-preferring triple reuptake inhibitor for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) study is a phase 2b/3a clinical trial designed to assess the safety and efficacy of amitifadine. A total of 342 MDD patients were randomized at 39 centers in the US. Top-line results are expected by the end of 1Q 2013.
